Modified Radical Mastectomy Biopsy with ER, PR, HER2/neu Panel in UAE | 1100 AED | 2026 DHA Guidelines

تحليل خزعة الثدي بعد استئصال الثدي الجذري المعدل مع مستقبلات الإستروجين والبروجستيرون وHER2/neu في الإمارات | 1100 درهم | معتمد من هيئة الصحة بدبي

Executive Summary

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

الملخص التنفيذي

يقدم هذا التحليل النسيجي تشخيصًا دقيقًا لحالة مستقبلات الهرمونات وجين HER2/neu في أنسجة الثدي بعد الاستئصال الجذري المعدل، مما يساعد في توجيه العلاج الهرموني والموجّه وفقًا لأعلى معايير هيئة الصحة بدبي.

Overview

This histopathology panel assesses estrogen receptor (ER), progesterone receptor (PR), and HER2/neu status on tissue obtained from a modified radical mastectomy. The results guide adjuvant endocrine therapy and targeted anti‑HER2 treatments, directly impacting survival outcomes.

يقوم هذا التحليل النسيجي بتقييم مستقبلات الإستروجين والبروجستيرون وبروتين HER2/neu في أنسجة الثدي المستأصلة جراحياً، مما يساعد في تحديد خيارات العلاج الهرموني والموجّه.

Feature	Our Test (Modified Radical Mastectomy Panel)	Standard Biopsy Marker Testing
Precision	Comprehensive ER/PR/HER2 via IHC with reflex FISH if HER2 2+ (equivocal)	Often only ER/PR by IHC; HER2 may be omitted
Methodology	ISO‑accredited histopathology with DHA‑approved protocols	Variable lab standards
Turnaround Time	6 working days	7–14 days typical

Physician Insight & Safety Protocol

"As a surgical pathologist, I urge patients to understand that ER/PR/HER2 results must be integrated with tumor grade and staging. No single marker should dictate therapy without a multidisciplinary discussion. Your oncologist will correlate these findings with your overall clinical picture." — Dr. PRABHAKAR REDDY, DHA License: 61713011

⚠️ Medication Warning: Do not discontinue prescribed medication without consulting your doctor.

Safety Exclusion Criteria & Red Flags

Exclusion: Active infection at surgical site, severe bleeding disorders, or inability to consent.
Red Flags: Sudden severe pain, excessive bleeding, or signs of wound infection after biopsy—seek immediate medical attention.
Minors: In compliance with UAE CDS Law 2026, this test is not performed on minors without legal guardian consent and clinical necessity.

Patient FAQ & Clinical Guidance

1. What do ER, PR, and HER2/neu results indicate for my treatment?

Snippet: ER/PR positivity directs hormonal therapy like tamoxifen or aromatase inhibitors, while HER2 amplification qualifies you for targeted drugs such as trastuzumab. (إيجابية مستقبلات الهرمونات توجه العلاج الهرموني، وتضخم HER2 يؤهلك للعلاج الموجّه.)

2. Why is this performed on mastectomy tissue instead of a core biopsy?

Snippet: The entire tumor specimen provides the most accurate receptor status, especially for heterogeneous cancers where biopsy may miss key areas. (عينة الورم الكامل تعطي أدق حالة للمستقبلات، خاصةً في السرطانات غير المتجانسة.)

3. How long until I receive the results and how are they reported?

Snippet: Results are delivered within 6 working days as a DHA‑recognized histopathology report accessible via secure portal and doctor consultation. (تُسلَّم النتائج خلال 6 أيام عمل عبر تقرير نسيجي معتمد من هيئة الصحة.)

This service complies with Federal Decree-Law No. 41 of 2024 (Art. 87), UAE PDPL (Data Privacy), and CDS Law 2026. Laboratory is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).

دعم ثنائي اللغة متاح